Abstract:Objective: To evaluate the effect of linaclotide treatment on patient confidence in bowel movement (BM) success, completeness, and ease, predictability of BM timing, and on treatment satisfaction in chronic idiopathic constipation (CIC) patients with prominent abdominal bloating.Methods: Post-hoc analyses were performed on data from a phase 3b, randomized, double-blind, placebo-controlled trial of linaclotide in patients who met modified Rome II criteria for CIC and had abdominal bloating ≥5 (0-10-point numerical rating scale).Patients were randomized to linaclotide 145 μg (n=154), 290 μg (n=160), or placebo (n=173) once daily.Assessments of patient confidence included confidence in having a BM at least once every other day, producing stool when going to the bathroom with an urge to have a BM, feeling completely empty after having a BM, and occurrence of BMs without straining, each measured weekly in the two-week pretreatment period and 12-week treatment period using a 3-point Likert scale (1=Not at all; 2=Somewhat; 3=Very).Patients' ability to predict BM timing after taking study medication was measured weekly in the 12-week treatment period using a 3-point Likert scale (1=Not at all; 2=Somewhat; 3=Very).Patient satisfaction with the study medication's ability to relieve constipation symptoms was measured using a 5point Likert scale (1=Not at all; 2=A little; 3=Moderately; 4=Quite; 5=Very).Data were averaged over the pretreatment period and each of the three (4-week) study months.Treatment and time effects were analyzed (for the intent-to-treat population) within a repeatedmeasures linear model.Results: Table 1 displays the study results.No differences were observed between treatment arms for any outcomes during the pretreatment period.Prior to treatment initiation, 79% of patients reported no confidence in having successful, complete BMs without straining.There was an apparent dose-response on improvement over time across all outcomes, with statistically significant differences in improvement observed between linaclotide (both doses) and placebo (all p<0.0001).Linaclotide-treated patients had significantly greater confidence in BM frequency, completeness of evacuation, and the occurrence of BMs without straining than placebo-treated patients.Figure 1 shows results for patient confidence in BM frequency.Patients treated with linaclotide were statistically significantly more likely to be able to predict the timing of their BMs and were more satisfied with treatment than patients on placebo.Conclusions: Linaclotide treatment improves patient confidence in BM success, completeness, and ease as well as patients' ability to predict BM timing.Improvement in specific BM attributes may be an important driver of treatment satisfaction.

The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study

Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation: Chinese Sub-Cohort Analysis of a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.

Linaclotide in Irritable Bowel Syndrome with Constipation: A Phase 3 Randomized Trial in China and Other Regions

Su2034 Diagnosis of Small Intestinal Bacterial Overgrowth by Lactulose Hydrogen Breath Test with Scintigraphic Oro-Caecal Transit Test: Methodological Validation of Diagnostic Criteria in Healthy Controls and Patients with Diarrhea Predominant Irritable Bowel Syndrome

The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation

Efficacy and Safety of Lubiprostone for the Treatment of Functional Constipation in Chinese Adult Patients: A Multicenter, Randomized, Double‐blind, Placebo‐controlled Trial

Examining linaclotide for the treatment of chronic idiopathic constipation

Yunpi Rougan Prescription in Treating Constipation-Predominant IBS: Clinical Observation and Gut Microbiota Effects

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

Sa1721 Dedifferentiation/Metaplasia of Gastric Chief Cells Depends on Normal Lysosomal Function

Cross-Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment

An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study

Application of linaclotide in bowel preparation for colonoscopy in patients with constipation: A prospective randomized controlled study

Sequential laxative-probiotic usage for treatment of irritable bowel syndrome: a novel method inspired by mathematical modelling of the microbiome

Efficacy of Probiotic Compounds in Relieving Constipation and Their Colonization in Gut Microbiota

Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial

Fecal Microbiota Transplantation Combined with a Low FODMAP Diet for the Treatment of Irritable Bowel Syndrome with Predominant Diarrhea

Effects of complex probiotics on intestinal function and its regulatory mechanism in patients with constipation

Correction To: Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China

In vitro Study of Bifidobacterium lactis BL-99 With Fructooligosaccharide Synbiotics Effected on the Intestinal Microbiota